key: cord-0878997-qlflyq5s authors: Giadone, Richard M.; Mithal, Aditya; Miller, Gregory J.; Matte, Taylor M.; Yeung, Anthony K.; Dowrey, Todd W.; Werder, Rhiannon B.; Miller, Nancy S.; Andry, Christopher D.; Vanuytsel, Kim; Murphy, George J. title: qRT-PCR Platforms for Diagnosing and Reporting SARS-CoV-2 Infection in Human Samples date: 2020-09-15 journal: STAR Protoc DOI: 10.1016/j.xpro.2020.100102 sha: ae0f90d0722f515eb684290a9fe8dce8eb22e549 doc_id: 878997 cord_uid: qlflyq5s The protocols herein outline the use of qRT-PCR to detect the presence of SARS-CoV-2 genomic RNA in patient samples. In order to cope with potential fluctuations in supply chain and testing demands and to enable expedient adaptation of reagents and assays on hand, we include details for three parallel methodologies (one- and two-step singleplex and one-step multiplex assays). The diagnostic platforms described can be easily adapted by basic science research laboratories for SARS-CoV-2 diagnostic testing with relatively short turnaround time. For complete details on the use and execution of this protocol, please refer to Vanuytsel et al. (2020). The protocols herein outline the use of qRT-PCR to detect the presence of SARS-CoV-2 genomic RNA in patient samples. In order to cope with potential fluctuations in supply chain and testing demands and to enable expedient adaptation of reagents and assays on hand, we include details for three parallel methodologies (one-and two-step singleplex and one-step multiplex assays). The diagnostic platforms described can be easily adapted by basic science research laboratories for SARS-CoV-2 diagnostic testing with relatively short turnaround time. For complete details on the use and execution of this protocol, please refer to Vanuytsel et al. (2020) . The assays described herein are commonplace in molecular and cellular biology laboratories across the world. To this end, several academic, basic science research laboratories have already contributed to COVID-19 testing during the height of the pandemic (Vanuytsel et al., 2020 , IGI Testing Consortium 2020 . As demonstrated, it is conceivable for university laboratories to implement the included protocols in an effort to aid in community surveillance testing to enable deep contact tracing as well as to assist local hospitals in keeping up with testing demands with relatively short turnaround times in the event of a second wave of infections. As stated above, as supply chains and testing requirements fluctuate, utilizing several assays (e.g., single-and multiplex assays) will enable laboratories to remain flexible and simultaneously meet demand. To ensure best practices in the implementation of these in-house platforms, it is crucial to perform appropriate validation studies as outlined by the United States Centers for Disease Control and Prevention (CDC) and Food and Drug and Administration (FDA). As outlined in Vanuytsel et al., 2020 , it is possible for basic science research laboratories to obtain CLIA licensure -necessary for diagnostic reporting of patient samples -as extensions of affiliated, relevant hospital departments. 2 infection in patient samples (see File S1), positive results are indicative of the presence of SARS-CoV-2 nucleic acid; however, clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status. Positive results do not rule out bacterial infection or co-infection with other viruses. Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for patient management decisions. Negative results must be combined with clinical observations, patient history, and epidemiological information. CRITICAL: The single-and multiplex protocols outlined below are based on FDA approved EUA applications filed by Boston Medical Center (BMC) and the Center for Regenerative Medicine (CReM) of BMC and Boston University as well as ThermoFisher for use in diagnosing patient samples with SARS-CoV-2 infection. Significant changes to said assays may require users to file for an additional EUA application requiring independent validation experiments to be performed. With this being said however, depending on the stability of existing supply chains, it may be necessary to utilize slightly different reagents or equipment. We recommend contacting the FDA to determine if proposed deviations from said protocols will be covered under their original EUA, or if they require further bridging and/or validation studies before they can be used for diagnostic purposes. While small changes to the listed protocols are likely covered under their associated EUA, it is best practice to perform optimization and validation experiments to ensure equivalent outcomes when running these protocols via different methodologies/reagents. Timing: 15 min per patient sample Note: Healthcare providers will take respiratory sample and insert swab into viral transport media utilizing BD Universal Transport Media (UTM) 3-mL collection kit with flexible minitip flocked swab (BD, Cat. No. 220531). 1. Transfer 300 mL of patient sample (e.g., UTM or saliva) to an RNase free microcentrifuge tube. Pause Point: Prior to sample inactivation and RNA extraction, patient samples can be stored at 4 C for short-term storage (e.g., 16-20 h) or À20 C for long-term storage (e.g., 48-72 h). Note: If testing saliva samples for the presence of SARS-CoV-2, add 20 mL proteinase K (20 mg/mL stock) to each sample and vortex for 30 s prior to buffer RLT addition as described previously (Ott et al., 2020; Wyllie et al., 2020) . Timing: 3 h for 46 samples assuming one operator Note: To control for the extraction process and sample stability, it is best practice to receive previously confirmed positive and negative patient samples and repeat the entire protocol (from sample inactivation to running the qRT-PCR assay of choice). Note: Total volume of inactivated patient sample (1.2 mL) is larger than the maximum capacity of Qiagen RNeasy Mini Kit spin column (700 mL). Add 600 mL of sample, perform the first spin, discard flowthrough, add the remaining 600 mL to the same spin column, and proceed as written in the manufacturer's protocol. Note: During extraction of RNA from saliva samples, due to sample viscosity, it may be necessary to perform additional spin steps of the spin column. Pause Point: Extracted/purified RNA samples can be stored at À80 C for long-term storage (e.g., 2 weeks). Timing: 30 min hands-on time, 3 h PCR program 6. To generate synthetic SARS-CoV-2 RNA standards, thaw commercially available synthetically engineered stock RNA (ATCC, Cat No. VR-3276SD) on ice. Note: Different viral standards are used for each assay described (two-and one-step singleplex assays and one-step multiplex assay). Note: The dilutions outlined below can be included in the qRT-PCR plate to generate a standard curve (i.e., C T value per concentration of positive control). If patient results are to be reported, per CDC and FDA, it is recommended that each run of the assays in question includes a positive control at maximum 53 the limit of detection (LoD) for each run of the assay. Please see CDC and FDA guidelines on how to determine the LoD for the given patient sample and/or molecular assay utilized. After identifying the LoD for a given assay, it may be necessary to adjust the concentrations included within the standard curves of each plate. CRITICAL: Confirm stock solution concentration with ATCC via catalog and lot numbers prior to cDNA generation. 7. Generate cDNA using 10 6 genome copies of stock RNA via reverse transcription (RT) reaction. See ''RT master mix for cDNA generation'' and ''cDNA generation PCR steps'' for RT reaction master mix recipe and PCR program, respectively. 8. After generating cDNA, make serial 1:10 dilutions of the 10 6 genome copies/mL solution in nuclease-free H 2 O until you have the following concentrations: 10 4 , 10 3 , 10 2 , 10 1 , 10 0 copies/mL. Timing: 30 min 9. To generate synthetic SARS-CoV-2 RNA standards, thaw commercially available synthetically engineered stock RNA (ATCC, Cat No. VR-3276SD) on ice. CRITICAL: Confirm stock solution concentration with ATCC via lot number prior to onestep singleplex assay. 10. From the stock solution of RNA, make a solution at 10 6 gc/mL in nuclease-free H 2 O. 11. From the 10 6 gc/mL solution, make serial 1:10 dilutions in nuclease-free H 2 O until you have the following dilutions: 10 4 , 10 3 , 10 2 , 10 1 , 10 0 copies/mL. Note: As the one-step singleplex assay has an RT reaction built into the qRT-PCR step, RNA is added directly to the qPCR plate and loaded master mix (i.e., no cDNA reaction is needed). Diluted RNA can be kept at À80 C for long-term storage. Timing: 30 min 12. To generate SARS-CoV-2 RNA standards, thaw TaqPath COVID-19 Combo Kit (ThermoFisher, Cat. No. A47814) positive control on ice. 13. From the stock solution of 10 4 gc/mL RNA, make serial 1:10 dilutions in nuclease-free H 2 O until you have the following dilutions: 10 4 , 10 3 , 10 2 , 10 1 , 10 0 copies/mL. Note: Similar to the one-step singleplex assay above, the one-step multiplex assay has an RT reaction included in the qRT-PCR step. As such, RNA is added directly to the qPCR plate and master mix (i.e., no RT reaction is needed). Diluted RNA can be kept at À80 C for long-term storage. CRITICAL: The two-and one-step singleplex assays detect the presence of N1 and N2 viral genes. The one-step multiplex assay detects the presence of N, S, and ORF1ab. It is Please cite this article in press as: Giadone et al., qRT-PCR Platforms for Diagnosing and Reporting SARS-CoV-2 Infection in Human Samples, STAR Protocols (2020), https://doi.org/10. 1016/j.xpro.2020.100102 important to note that the ATCC RNA standard referenced contains regions of the OR-F1ab, N, and Env viral genes. The primer/probe sets utilized in the two-and one-step singleplex assays span regions of the N1 and N2 genes present in the ATCC RNA positive control, while the one-step multiplex assay does not. Utilizing this ATCC RNA standard with the one-step multiplex assay will result in insufficient detection of the ORF1ab, N, and S genes. Please note however, that it is possible to obtain full-length SARS-CoV-2 genomic RNA from ATCC (Cat. No. VR-1986D) to use in lieu of or addition to the TaqPath COVID-19 Combo Kit positive control. Aliquoting Primer/Probe Sets for Two-and One-Step Singleplex Assays Timing: 15 min 14. Thaw N1, N2, and RP primer/probe sets on ice, protected from light. 15. Label individual nuclease-free microcentrifuge tubes with primer/probe set name. 16. Transfer required volume to appropriate tubes. The two-and one-step singleplex assays both use the same primer/probe sets (IDT, Cat. No. 110006606) . As a result, this step is the same for the two assays. The one-step multiplex assay has primer/probe sets within one reagent. While excessive freeze/thaw cycles (10 at most) should be limited, making individual aliquots is not necessary. Note: Primer/probe sets can be kept at À20 C for long-term storage. Determine the appropriate volume for each aliquot to minimize freeze/thaw cycles (e.g., one aliquot contains enough primer/probe set for one full qRT-PCR plate). Note: Reagents labeled with ''*'' denote those specific to the two-step singleplex assay, reagents labeled with ''y'' denote those specific to the one-step singleplex assay, reagents with ''^'' denote those specific to the one-step multiplex assay. All other listed reagents are common to all protocols. The BMC-CReM COVID-19 test is to be used with: Alternatives: RNA extraction: The protocols described throughout this text first rely on the extraction of RNA from patient samples via the Qiagen RNeasy Minikit procedure. As demands for testing are likely to fluctuate in the future, this kit may not be available to researchers. To combat this, an alternative approach would be to utilize a phenol/chloroformbased RNA extraction methodology (e.g., TRIzol, ThermoFisher, Cat. No. 15596026). Although cheap and potentially yielding larger quantities of RNA, it is important to note that this technique generates hazardous chemical waste requiring appropriate storage -a potentially limiting factor if processing large sample numbers. Alternatives: Thermocycler and qPCR machines: Here, we utilized the QuantStudio 6 Flex Real-Time PCR System, 384-well, desktop (Cat. No. 4485701) (software version 1.3) and Mastercycler Nexus X2 (Cat. No. 6336000023) (software version 3.5.1) for RT reaction and qPCR, respectively. Other thermocyclers and/or qRT-PCR platforms can be utilized for these steps as long as the appropriate cycling parameters are set into the machine prior to running. We recommend validating new thermocycler and/or qPCR machines by running either an appropriate standard curve and/or previously confirmed positive and negative patient samples through the entire assay protocol. Timing: 5.5 h post RNA extraction to results The two-step singleplex assay first generates cDNA from RNA standards or RNA extracted from patient samples via an independent RT reaction. RT-generated cDNA is subsequently loaded onto a qRT-PCR machine and interrogated for the presence of SARS-CoV-2 viral genes (here, nucleocapsid N1 and N2) and human RNase P (RP) as an internal control for extraction and sample stability. C T values for N1, N2, and RP are in turn used to make diagnostic decisions regarding SARS-CoV-2 infection. 1. Generation of cDNA from RNA (standards or patient samples) a. Prepare master mix for reverse transcriptase reaction in a microcentrifuge tube. b. Mix by briefly pipetting or gently vortexing. c. Pipette 5.8 mL of master mix into PCR strip tubes. d. Add 14.2 mL RNA to respective PCR strip tube and gently mix by pipetting 5-10 times. Note: In order to control for potential contamination occurring during cDNA generation and eventual qPCR plating, a no template control (NTC) should be used. Here, the NTC is defined as nuclease-free H 2 O at 14.2 mL in place of RNA in the RT reaction. e. Spin PCR strip tubes briefly in a mini-centrifuge (e.g., Spectrafugeä mini-centrifuge, Millipore Sigma, Cat. No. S7816) at 2,000 3 g for approximately 10 s. f. Insert tubes into Mastercycler Nexus GX2 thermocycler and run the following program: Pause Point: RT (reaction can be left at 4 C step in PCR machine 16-20 h). Moreover, cDNA can be kept at À20 C for long-term storage (e.g., months) or 4 C for short-term storage (e.g., 1 week). 2. Newly generated cDNA is subsequently diluted by adding 40 mL nuclease-free H 2 O for a final total volume of 60 mL. Note: This volume allows for a patient sample's cDNA to be re-run in the event of an inconclusive result. 3. Preparation of master mix for qPCR and respective plate setup a. Thaw 23 TaqMan Fast Advanced Master Mix on ice. Note: Once thawed, master mix can be stored at 4 C. b. Thaw primer/probe set on ice, protected from light. c. Mix Master Mix and primer/probes by inversion 5 times, then centrifuge for 5-10 s. d. Label one microcentrifuge tube for each primer/probe set (i.e., three tubes total: N1, N2, and RP). e. Determine the number of reactions (N) to set up per assay. For a standard curve of 5 concentrations with two replicates each, you will need 48 wells. Account for margin of error. Note: Technical duplicates are used for each sample and primer/probe set. For research purposes, as N1 and N2 transcripts are being probed for in separate wells, it may not be necessary to utilize technical duplicates -saving time and reagents while at the same time increasing sample throughput. f. Prepare the above mixture and mix by pipetting slowly up and down. g. If mixed via gentle vortexing, centrifuge each reaction mix for 5-10 s. h. Dispense 10 mL each master mix reaction into a 384-well plate. i. Gently vortex and centrifuge all standard and any samples. j. Add 5 mL each standard or sample to the 384-well plate containing the reaction mixture. In the two-step singleplex assay, 56 patient samples can be run per plate. Figure 1 depicts Note: In an effort to limit the potential for errors in interpreting qRT-PCR results, the use of an automated results reporting script is highly recommended. To this end, please see our recently developed R script capable of importing and interpreting C T values from qRT-PCR of patient samples in an unbiased manner (available at https://github.com/TaylorMatte/ Quant6-Covid_Analysis). The R scripts included within this link contain comments which provide step-by-step instructions. Video S1 describes how to use this script to interpret singleplex assay results based on the diagnostic matrix outlined above in Table 1 . Sample input and output files can be seen in Figure 2 . Sample plate layout for a full 384-well qRT-PCR plate. Green shading denotes wells containing N1 primer/probe sets, orange shading denotes wells containing N2 primer/probe sets, and blue shading denotes wells containing RP primer/probe sets. The two-and one-step singleplex assays are able to run 56 patients samples on each 384-well qRT-PCR plate. Each sample and primer/probe set is ran in technical duplicate. Wells labeled 10 4 -10 0 represent the standard curve samples, ptXX denotes individual patient samples (here, 01-56), NTC refers to no template control (H 2 O in the place of RNA in the RT reaction), POS and NEG represent previously identified positive and negative patient samples, respectively. Step Cycles Temp Time One-Step Singleplex Assay The one-step singleplex assay relies on a RT reaction programmed within the qPCR step. As with the two-step singleplex assay, the one-step platform assesses for the presence of SARS-CoV-2 viral genes N1 and N2, with RP as an internal control for extraction and sample stability. C T values for N1, N2, and RP are subsequently interpreted using the identical matrix utilized for the two-step singleplex assay (Table 1) . Step RT-qPCR Master Mix and primer/probe sets on ice, protected from light. b. Mix master mix reagent and primer/probes by inversion 5 times, then centrifuge for 5-10 s. c. Label one microcentrifuge tube for each primer/probe set (i.e., three tubes in total, for N1, N2, and RP). d. Determine the number of reactions (N) to set up per assay. For a standard curve with two replicates, you will need 48 wells. Account for margin of error. Note: Technical duplicates are used for each sample and primer/probe set. As stated previously, for research purposes, as N1 and N2 transcripts are being probed for in separate wells, it may not be necessary to utilize technical duplicates -saving on time and reagents while at the same time increasing sample throughput. e. Prepare the above mixture and mix by pipetting slowly up and down. f. If mixed via gentle vortexing, centrifuge each reaction mix for 5-10 s. g. Dispense 17.5 mL each master mix reaction into a 384-well plate. h. Gently vortex and centrifuge each standard and any samples. i. Add 2.5 mL each standard or samples to the 384-well plate containing the reaction mixture. In the one-step singleplex assay, 56 patient samples can be run per plate. Figure 1 depicts a sample plate layout for a full 384-well plate including standard curve, NTC, and positive and negative controls with technical duplicates -this is the same layout as the twostep singleplex assay, described above. Please cite this article in press as: Giadone et al., qRT-PCR Platforms for Diagnosing and Reporting SARS-CoV-2 Infection in Human Samples, STAR Protocols (2020), https://doi.org/10. 1016/j.xpro.2020.100102 c. Load the 384-well plate and start the run. d. Generate a standard curve for N1, N2. In the standard curve, RP assays should not show significant amplification. e. Please see Table 1 for US CDC panel recommended interpretations for diagnostic reporting for the one-step singleplex assay. Note: As with the two-step singleplex assay, in this platform, reactions reading a C T value of R40 are taken as negative. C T values below 40 are classified as positive. As stated above, here we classify a C T value <40 for RP as positive. Other FDA approved EUAs utilizing similar qRT-PCR-based methodologies for diagnosing SARS-CoV-2 infection utilize a more stringent cutoff for this internal housekeeping gene (e.g., positive values are only considered for C T values <35). If employing this cutoff, it is important to adjust the respective results interpretation table. Timing: 3 h post RNA extraction to results The one-step multiplex assay relies on a RT reaction programmed within the qPCR step. Unlike the previous assays, the one-step multiplex assay tests patient samples for the presence of SARS-CoV-2 S, N, and ORF1ab genes. In place of RP as a control for RNA extraction and sample stability, this platform assesses the presence of MS2 transcript -a bacteriophage transcript not present in human or SARS-CoV-2 genomes. This depends on spiking in MS2 RNA into patient sample prior to RNA extraction (described in Before You Begin section above). C T values for S, N, ORF1ab, and MS2 are subsequently interpreted using the diagnostic decision matrix in Table 2 CRITICAL: For the one-step multiplex assay, utilize the RNA standards provided within the TaqPath COVID-19 Combo Kit. Different synthetic RNAs may contain partial regions of the SARS-CoV-2 genome and therefore might not include the N, S, and ORF1ab sequences assayed for in the COVID-19 Real-Time PCR Assay Multiplex system. e. Prepare the above mixture and mix by pipetting slowly up and down. f. If mixed via gentle vortexing, centrifuge each reaction mix for 5-10 s. g. Dispense 20 mL master mix reaction into a 384-well plate. h. Gently vortex and centrifuge each standard and any sample. i. Add 5 mL each standard or sample to the 384-well plate containing the reaction mixture. In the one-step multiplex assay, 186 patient samples can be ran per plate. Figure 3 depicts a sample plate layout for a full 384-well plate including standard curve and negative control, with technical duplicates. j. Centrifuge the 384-well plate for 30 s using plate spinner. 9. qPCR a. Turn on the machine and allow the block to equilibrate. b. Set up the following program: Total run time: $1 h 15 min CRITICAL: Prior to initializing the run, designate each gene target with the appropriate fluorophore (N=VIC, S=ABY, ORF1ab=FAM, MS2=JUN). c. Load the 384-well plate and start the run d. Generate a standard curve for N, ORF1ab, and S. MS2 should be present at roughly equivalent amounts throughout all samples (not including standard curve) ran. e. Please see Table 2 for US CDC panel recommended interpretations for diagnostic reporting for the one-step multiplex assay adapted from the TaqPath COVID-19 Combo Kit manual. Note: Reactions reading a C T value of R40 are taken as negative. C T values below 40 are classified as positive. There should be minimal fluorescence emitted from NTC wells via qRT-PCR. If NTC wells have a C T value <40, this implies contamination of the qRT-PCR reaction and therefore the plate/run is not used for diagnostic decisions. In this case, the assay will be repeated from the RT-PCR step using residual extraction material. If the repeat test result is positive for these targets, all samples will need to be re-extracted and re-tested. The positive control cDNA must have detectible C T values (<40 C T ) for N1 and N2 (not RP) for concentrations 53 (and above) the determined LoD of the assay for the plate to be valid. If the positive control cDNA fails to yield N1 and N2 C T values (i.e., undetected) for concentrations a minimum of 53 the LoD of the assay, the plate/run is not used for diagnostic decisions. In this case the qRT-PCR reaction needs to be repeated for all samples using residual extraction material. If the repeat test result for N1 and N2 is negative again, all samples will need to be re-extracted and re-tested. Figure 4 depicts expected results for a sample standard curve composed of positive control cDNA of various concentrations. If a sample shows no amplification for N1 and N2 and also fails to show detectable levels for RP, the sample is deemed invalid and needs to be re-extracted and re-tested. If N1 or N2 are not detected in the positive extraction control sample, this suggests sample degradation and/or faulty RNA extraction -the plate/run should not be used for diagnosis. If N1 or N2 are detected in the negative extraction control, this suggests contamination -the plate/run should not be used for diagnosis. In this case, all samples included on the plate need to be re-extracted and retested. Figure 4 depicts sample C T values for N1, N2, and RP probes in positive patient samples. CRITICAL: If results from control samples deviate from what is expected, do not generate any diagnostic reports from the respective qRT-PCR run. Discard the plate and re-run samples depending on which control failed. See ''Troubleshooting'' section below for interpretation of controls. There should be minimal fluorescence emitted from NTC wells via qRT-PCR. If NTC wells have a C T value <40, this implies contamination of the qRT-PCR reaction and therefore the plate/run is not used for diagnostic decisions. In this case, the assay will be repeated from the RT-PCR step using residual extraction material. If the repeat test result is positive for these targets, all samples will need to be re-extracted and re-tested. The positive control cDNA must have detectible C T values (<40 C T ) for N, S, and ORF1ab for concentrations 53 and above the determined LoD of the assay for the plate to be valid. If the positive control cDNA fails to yield N, S, or ORF1ab C T values (i.e., undetected) for concentrations at a minimum of 53 the LoD, the plate/run is not used for diagnostic decisions. In this case, the qRT-PCR reaction needs to be repeated for all samples using residual extraction material. If the repeat test result for N, S, and ORF1ab is negative again for all concentrations of this control, all samples will need to be reextracted and re-tested. If a sample shows no amplification for any target tested while also failing to show detectable levels for MS2, the sample is deemed invalid and needs to be re-processed and re-tested. Pending CLIA certification and/or FDA approval, the protocols herein can be utilized to diagnose patient samples with the presence of SARS-CoV-2 genomic RNA. With this said, these assays are only capable of identifying viral RNA present at a singular timepoint (namely, the time of sample collection). It is possible that immediately after a sample is obtained from an individual that she or he can become infected with SARS-CoV-2. Similarly, it is possible that levels of viral RNA (and therefore the probability of detection) may fluctuate throughout the course of infection and/or disease. Furthermore, it is unclear how symptomatology correlates with C T values of viral targets. If there is an inverse correlation with disease severity/progression and said C T values (i.e., a person at the earliest stages of infection or an asymptomatic carrier has a high N1/N2/ORF1ab/S C T value), it is possible that infected individuals may be reported as negative by these assays. It is important to consider obtaining multiple samples from an individual/patient throughout her or his treatment. Additionally, as stated above, negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for patient management decisions. Negative results must be combined with clinical observations, patient history, and epidemiological information. Problem 1 Inappropriate Results from Controls As noted above, in the event that results from control samples deviate from what is expected, this indicates a step in the accompanying protocol failed. To ensure accurate reporting, all data retrieved from the respective run is discarded and the assay is repeated at the earliest failed step (as determined by the failed control). For example, in the event of contamination during the cDNA generation step, repeat the protocol at this stage. Tables 3 and 4 represent interpretations of controls for the singleplex and multiplex assays, respectively. Note: NTC in the two-step singleplex assay refers to nuclease-free H 2 O ran in the place of RNA in the cDNA generation step (i.e., RT reaction). In the one-step singleplex assay, NTC refers to nuclease-free H 2 O ran in the place of RNA sample in the qRT-PCR machine. All other controls listed are common in both platforms. It is sometimes possible to find spurious curves on the qRT-PCR results for specific SARS-CoV-2 target genes ( Figure 5) . Unfortunately, the qRT-PCR software does not necessarily identify these curves as technical artifacts. As a result, the machine reports the C T value for the sample with said curve as if it were appropriate. Frequently, these C T values are low (e.g., $5 vs. $30). While the reporting algorithm should discard samples with one spurious curve and one undetected replicate as inconclusive, as a quality control step, it is worthwhile to briefly survey all curves generated from the run to preemptively identify artifactual curves which may yield unreliable C T values. (Please note that despite the low C T value for the spurious curve described above, it is possible to get such a curve at a later value with abnormal shape upon analyzing on the qRT-PCR machine.) Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Dr. Kim Vanuytsel (kimvan@bu.edu). There were no unique reagents generated in this study nor are there any restrictions to availability. To access the R script enabling automated reporting into hospital EMR, please visit: https://github. com/TaylorMatte/Quant6-Covid_Analysis. Video S1 demonstrates all of the steps required in utilizing said script for automated result reporting. Blueprint for a pop-up SARS-CoV-2 testing lab Saliva collection and RNA extraction for SARS-CoV-2 detection. protocols Rapid implementation of an FDA-approved SARS-CoV-2 diagnostic test at a large academic safety-net hospital Saliva is more sensitive for SARS-CoV-2 detection in COVID-19 patients than nasopharyngeal swabs The authors declare no competing interests.